Expert Interview
Getting a clinician's perspective on Ardelyx's XPHOZAH (tenapanor) and the company's decision to not file for TDAPA
Ticker(s): ARDXInstitution: USC
- Associate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC.
- Treats patients with both HRS1 and HRS2 and over 200 patients with Anemia-CKD.
- Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.
Roughly how many patients with ESRD do you manage on dialysis?
Added By: c_adminCan you explain TDAPA and the CMS bundle to understand implications on XPHOZAH?
Added By: c_adminWhat are the challenges you encounter in managing hyperphosphatemia in CKD patients, especially those on dialysis?
Can you explain why you believe Xphozah (tenapanor) is a game changer compared to existing phosphate binders like Renvela and Velphoro?
Could you provide insights into the sodium-hydrogen exchanger mechanism in Xphozah and its benefits in reducing phosphorus absorption and bowel movement issues?
What are your thoughts on Ardelyx's decision not to apply for TDAPA for Xphozah, and how might this impact access and physician prescription practices?
Added By: catalin_adminHow do you see Xphozah impacting the treatment landscape for CKD in the next few years, particularly in relation to its expected integration with Medicare coverage and other oral agents?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
